Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18705335 | 0.89 | CYP1A2 (0.35) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL557138 | 0.86 | TSHR (0.40) | ALDH1A1MEN1KMT2AESR1 | |
| SCHEMBL1943663 | 0.86 | TSHR (0.40) | ALDH1A1MEN1KMT2AESR1 | |
| SCHEMBL3719747 | 0.80 | ALDH1A1 (0.34) | ALDH1A1KMT2A | |
| SCHEMBL30080738 | 0.79 | KMT2A (0.32) | ALDH1A1KMT2A | |
| SCHEMBL31674997 | 0.79 | MEN1 (0.32) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL21798718 | 0.78 | TSHR (0.42) | KMT2A | |
| SCHEMBL2159701 | 0.77 | — | — | |
| SCHEMBL6847342 | 0.77 | MEN1 (0.31) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Citric Acid SCHEMBL8916871 | 0.76 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299383-B1 | SPECIFIC MODIFICATION OF ANTIBODY WITH IGG-BINDING PEPTIDE | UNIV KAGOSHIMA (JP) | 2025-12-03 | — | — | EP | claimed |
| CN-119776344-A | Method for simultaneously enriching disordered protein and combining three-dimensional genome structure | 中国人民解放军军事科学院军事医学研究院 | 2025-04-08 | — | — | CN | claimed |
| EP-3470418-B1 | SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IGG-BINDING PEPTIDE | UNIV KAGOSHIMA (JP) | 2024-07-31 | — | — | EP | claimed |
| EP-4107284-A1 | IN SITU ANALYSIS OF CHROMATIN INTERACTION | 10X Genomics, Inc. (US) | 2022-12-28 | — | — | EP | claimed |
| CN-115109367-A | Injectable hydrogel and preparation method and application thereof | 苏州凝智新材料发展有限公司 | 2022-09-27 | — | — | CN | claimed |
| EP-3544637-B1 | NATIVE OMV-ANTIGEN CONJUGATES AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-11-11 | — | — | EP | claimed |
| EP-3171171-B1 | RECOMBINANT DEAMIDATED GLIADIN ANTIGEN | BIO RAD LABORATORIES (US) | 2018-07-18 | — | — | EP | claimed |
| EP-2494075-B1 | TEMPLATED NANOCONJUGATES | UNIV NORTHWESTERN (US) | 2018-04-04 | — | — | EP | claimed |
| EP-2788760-B1 | RECOMBINANT DEAMIDATED GLIADIN ANTIGEN | BIO RAD LABORATORIES INC (US) | 2017-02-15 | — | — | EP | claimed |
| EP-1853634-B1 | ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-08-10 | — | — | EP | claimed |
| EP-1776389-B1 | SIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-06-29 | — | — | EP | claimed |
| EP-2659901-B1 | Recombinant deamidated gliadin antigen | BIO RAD LABORATORIES (US) | 2015-01-21 | — | — | EP | claimed |
| EP-2444807-B1 | MONO- AND DINITROPYRAZOLE HAPTEN CONJUGATES | VENTANA MED SYST INC (US) | 2014-06-11 | — | — | EP | claimed |
| EP-2132332-B1 | MEASUREMENT OF AN INSOLUBLE ANALYTE IN A SAMPLE | HIGH THROUGHPUT GENOMICS INC (US) | 2014-01-22 | — | — | EP | claimed |
| EP-2276499-B1 | RECOMBINANT DEAMIDATED GLIADIN ANTIGEN | BIO RAD LABORATORIES (US) | 2013-06-12 | — | — | EP | claimed |
| EP-2126584-B1 | DIRECT MASS SPECTROMETRIC ANALYSIS OF DRUG CANDIDATES TARGETING PROTEIN COMPLEXES | COVALX AG (CH) | 2012-12-19 | — | — | EP | claimed |
| EP-2095129-B1 | DIRECT MASS SPECTROMETRIC ANALYSIS OF SELF-AGGREGATES OF THERAPEUTIC PROTEINS | COVALX AG (SE) | 2011-02-23 | — | — | EP | claimed |
| EP-1549350-B1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DE GMBH (DE) | 2008-09-24 | — | — | EP | claimed |
| WO-2006094826-A2 | METHOD FOR COUPLING ENZYMATICALLY ACTIVATED GLYCOCONJUGATES TO A HYDROXYALKYL STARCH | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-09-14 | — | — | WO | claimed |
| US-20250320544-A1 | IN SITU ANALYSIS OF CHROMATIN INTERACTION | 10X GENOMICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-3906065-B1 | PRR AGONIST FOR USE IN THE TREATMENT OF CANCER | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2025-04-30 | — | — | EP | disclosed |
| CN-119776344-A | Method for simultaneously enriching disordered protein and combining three-dimensional genome structure | 中国人民解放军军事科学院军事医学研究院 | 2025-04-08 | — | — | CN | disclosed |
| US-12215379-B2 | In situ analysis of chromatin interaction | 10X GENOMICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-12187817-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2025-01-07 | — | — | US | disclosed |
| CN-118236479-A | Glycoprotein-entrapped immune agonist conjugate vaccine and application thereof in preparing vaccine | 江南大学 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024028192-A1 | USE OF CONJUGATES OF HUMAN SERUM ALBUMIN AND PHOSPHOCHOLINE FOR BLOCKING C-REACTIVE PROTEIN | PENTRACOR GMBH (DE) | 2024-02-08 | — | — | WO | disclosed |
| US-20230374076-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | KODE BIOTECH LIMITED (NZ) | 2023-11-23 | — | — | US | disclosed |
| US-11766483-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | KODE BIOTECH LIMITED (NZ) | 2023-09-19 | — | — | US | disclosed |
| EP-3606561-B1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LTD (GB) | 2023-08-02 | — | — | EP | disclosed |
| EP-4169577-A1 | 4-AMINOPHENYLPHOSPHORYLCHOLINE COMPOUNDS FOR THE INHIBITION OF C-REACTIVE PROTEIN | Pentracor GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-4107284-A1 | IN SITU ANALYSIS OF CHROMATIN INTERACTION | 10X Genomics, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11484596-B2 | Optimized process for dimeric peptide-phospholipid conjugate | BRACCO SUISSE SA (CH) | 2022-11-01 | — | — | US | disclosed |
| EP-3897736-B1 | OPTIMIZED PROCESS FOR DIMERIC PEPTIDE-PHOSPHOLIPID CONJUGATE | BRACCO SUISSE SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| CN-114929733-A | Epitopes of regulatory T cell surface antigens and antibodies specifically binding thereto | 古德T细胞有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220202944-A1 | OPTIMIZED PROCESS FOR DIMERIC PEPTIDE-PHOSPHOLIPID CONJUGATE | BRACCO SUISSE SA (CH) | 2022-06-30 | — | — | US | disclosed |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220054476-A1 | SUSTAINED LOCAL DRUG LEVELS FOR INNATE IMMUNE AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220054478-A1 | MINIMIZATION OF SYSTEMIC INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20210353765-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | AVVINITY THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-11-18 | — | — | US | disclosed |
| US-20210346514-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | AVVINITY THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-11-11 | — | — | US | disclosed |
| EP-3897736-A1 | OPTIMIZED PROCESS FOR DIMERIC PEPTIDE-PHOSPHOLIPID CONJUGATE | Bracco Suisse SA (CH) | 2021-10-27 | — | — | EP | disclosed |
| US-20210254140-A1 | SITU ANALYSIS OF CHROMATIN INTERACTION | 10X GENOMICS INC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3863719-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Avvinity Therapeutics Limited (GB) | 2021-08-18 | — | — | EP | disclosed |
| EP-3863718-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Avvinity Therapeutics Limited (GB) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021153717-A1 | AFFINITY CHROMATOGRAPHY BASED ON ARTIFICIAL NUCLEIC ACID | 池田 壽文 | 2021-08-05 | — | — | WO | disclosed |
| US-20210214396-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | KODE BIOTECH LIMITED (NZ) | 2021-07-15 | — | — | US | disclosed |
| WO-2020145405-A1 | THREE-DIMENSIONAL DNA STRUCTURE INTERACTION ANALYSIS METHOD | 株式会社ステムリム | 2020-07-16 | — | — | WO | disclosed |
| WO-2020127124-A1 | OPTIMIZED PROCESS FOR DIMERIC PEPTIDE-PHOSPHOLIPID CONJUGATE | BRACCO SUISSE SA (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-20200147236-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2020-05-14 | — | — | US | disclosed |
| CN-108175855-B | Rabies immunogenic conjugate | 成都安特金生物技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-108187038-B | Rabies combined vaccine | 成都安特金生物技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-108295252-B | Method for preparing rabies combined vaccine | 成都安特金生物技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-3606561-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018220603-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | BOVIN NICOLAI VLADIMIROVICH (RU) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018185495-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2018-10-11 | — | — | WO | disclosed |
| US-20170157212-A1 | CDK MODULATORS AND METHODS FOR THE TREATMENT OF CANCER | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-06-08 | — | — | US | disclosed |
| WO-2016156469-A1 | GENOME ARCHITECTURE MAPPING ON CHROMATIN | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-10-06 | — | — | WO | disclosed |
| EP-1776389-B1 | SIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-06-29 | — | — | EP | disclosed |
| CN-102905690-B | Zwitterion reagent | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2016-03-30 | — | — | CN | disclosed |
| CN-102666879-B | Templated nanometer conjugate | NORTHWEST UNIVERSITY (US) | 2016-02-24 | — | — | CN | disclosed |
| CN-102782159-B | Compositions and methods for sequencing nucleic acids | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (CN) | 2016-01-20 | — | — | CN | disclosed |
| EP-2111237-B1 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING SPA (IT) | 2015-03-18 | — | — | EP | disclosed |
| CN-103349780-A | Conjugation of streptococcal capsular saccharides | NOVARTIS VACCINES & DIAGNOSTIC | 2013-10-16 | — | — | CN | disclosed |
| CN-101304765-B | Conjugation of streptococcal capsular saccharides | NOVARTIS VACCINES & DIAGNOSTIC | 2013-03-27 | — | — | CN | disclosed |
| US-20110286937-A1 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME | GIFU UNIVERSITY (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-1480681-B1 | COUPLING LOW-MOLECULAR SUBSTANCES TO A MODIFIED POLYSACCHARIDE | FRESENIUS KABI DE GMBH (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20110045568-A1 | METHOD FOR RESTORING BMP-RECEPTOR SIGNALING IN A CELL | FREIE UNIVERSITÄT BERLIN (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2269655-A2 | Coupling of low molecular weight substances to hydroxyalkyl starch | Fresenius Kabi Deutschland GmbH (DE) | 2011-01-05 | — | — | EP | disclosed |
| EP-2255787-A1 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOMES | Katayama Chemical Industries Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-2244727-A1 | A METHOD FOR RESTORING BMP-RECEPTOR SIGNALING IN A CELL | Freie Universität Berlin (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-1447081-B1 | Sugar-modified liposome and products comprising the liposome | NAT INST OF ADVANCED IND SCIEN (JP) | 2010-02-10 | — | — | EP | disclosed |
| EP-2111237-A2 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING S.p.A. (IT) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009106339-A1 | A METHOD FOR RESTORING BMP-RECEPTOR SIGNALING IN A CELL | FREIE UNIVERSITÄT BERLIN (DE) | 2009-09-03 | — | — | WO | disclosed |
| EP-2095824-A1 | A method for restoring BMP-receptor signaling in a cell | Freie Universität Berlin (DE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009074569-A1 | TARGETING AND THERAPEUTIC COMPOUNDS WITH A POLYPROLINE-COMPRISING SPACER AND GAS-FILLED MICROVESICLES COMPRISING SAID COMPOUNDS | BRACCO INTERNATIONAL BV (NL) | 2009-06-18 | — | — | WO | disclosed |
| US-7494776-B2 | Labeled complementary oligonucleotides to detect oligonucleotide-linked ligands | BECKMAN COULTER, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| CN-101304765-A | Conjugation of streptococcal capsular saccharides | NOVARTIS VACCINES & DIAGNOSTIC (IT) | 2008-11-12 | — | — | CN | disclosed |
| US-20080253961-A1 | Drug delivery; biocompatable polyesters; biodegradable glycolic acid-lactic acid nanoshell (PLGA); controlled release | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080226709-A1 | Phospholipid membrane preparation | NOF CORPORATION (JP) | 2008-09-18 | — | — | US | disclosed |
| WO-2008073458-A2 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING S.P.A. (IT) | 2008-06-19 | — | — | WO | disclosed |
| EP-1904651-A1 | LABELED COMPLIMENTARY OLIGONUCLEOTIDES TO DETECT OLIGONUCLEOTIDE-LINKED LIGANDS | Beckman Coulter, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080038329-A1 | T-CELL ACTIVATING AGENT | NOF CORPORATION (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20070286896-A1 | Therapeutic or Diagnostic Drug for Inflammatory Disease Comprising Targeting Liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2007-12-13 | — | — | US | disclosed |
| EP-1808181-A1 | Polysaccharide-cyclodextrin conjugates | B. BRAUN MELSUNGEN AG (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20070160657-A1 | Targeting and intestinal-absorption controlled liposome having sugar chain and therapeutic drug for cancer and diagnostic drug containing the liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2007-07-12 | — | — | US | disclosed |
| WO-2007008550-A1 | LABELED COMPLIMENTARY OLIGONUCLEOTIDES TO DETECT OLIGONUCLEOTIDE-LINKED LIGANDS | BECKMAN COULTER, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070009914-A1 | Labeled complimentary oligonucleotides to detect oligonucleotide-linked ligands | BECKMAN COULTER, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2006094826-A2 | METHOD FOR COUPLING ENZYMATICALLY ACTIVATED GLYCOCONJUGATES TO A HYDROXYALKYL STARCH | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| US-20060193906-A1 | Sugar-modified liposome and products comprising the liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2006-08-31 | — | — | US | disclosed |
| US-7070801-B2 | Sugar-modified liposome and products comprising the liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-1655038-A1 | TARGET-DIRECTED AND ENTERIC ABSORPTION-CONTROLLED LIPOSOME HAVING SUGAR CHAIN AND CANCER REMEDY AND DIAGNOSTIC CONTAINING THE SAME | National Institute of Advanced Industrial Science and Technology (JP) | 2006-05-10 | — | — | EP | disclosed |
| EP-1655022-A1 | REMEDY OR DIAGNOSTIC FOR INFLAMMATORY DISEASE CONTAINING TARGET-DIRECTING LIPOSOME | National Institute of Advanced Industrial Science and Technology (JP) | 2006-05-10 | — | — | EP | disclosed |
| US-20050266066-A1 | Phospholipid membrane preparation | NOF CORPORATION (JP) | 2005-12-01 | — | — | US | disclosed |
| EP-1480682-A1 | COUPLING PROTEINS TO A MODIFIED POLYSACCHARIDE | Biotechnologie Gesellschaft Mittelhessen MBH (DE) | 2004-12-01 | — | — | EP | disclosed |
| EP-1480681-A2 | COUPLING LOW-MOLECULAR SUBSTANCES TO A MODIFIED POLYSACCHARIDE | Biotechnologie Gesellschaft Mittelhessen MBH (DE) | 2004-12-01 | — | — | EP | disclosed |
| EP-1447081-A1 | Sugar-modified liposome and products comprising the liposome | National Institue of Advanced Industrial Science and Technology (JP) | 2004-08-18 | — | — | EP | disclosed |
| US-20040009500-A1 | Items with activated surface used for immobilisation of macromolecules and procedures for the production of such items | CHIMERA BIOTEC GMBH (DE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003074088-A2 | COUPLING LOW-MOLECULAR SUBSTANCES TO HYDROXYALKYL STARCH | BIOTECHNOLOGIE - GESELLSCHAFT MITTELHESSEN MBH (DE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074087-A1 | COUPLING PROTEINS TO A MODIFIED POLYSACCHARIDE | BIOTECHNOLOGIE - GESELLSCHAFT MITTELHESSEN MBH (DE) | 2003-09-12 | — | — | WO | disclosed |
| US-20030143267-A1 | Sugar-modified liposome and products comprising the liposome | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL | 2003-07-31 | — | — | US | disclosed |
| EP-1230213-A1 | ARTICLES HAVING AN ACTIVATED SURFACE FOR IMMOBILIZING MACROMOLECULES AND METHOD FOR PRODUCING SUCH ARTICLES | chimera biotec GmbH (DE) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001070681-A1 | ARTICLES HAVING AN ACTIVATED SURFACE FOR IMMOBILIZING MACROMOLECULES AND METHOD FOR PRODUCING SUCH ARTICLES | CHIMERA BIOTEC GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001070681-A1 | ARTICLES HAVING AN ACTIVATED SURFACE FOR IMMOBILIZING MACROMOLECULES AND METHOD FOR PRODUCING SUCH ARTICLES | CHIMERA BIOTEC GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054478-A1 | MINIMIZATION OF SYSTEMIC INFLAMMATION | CCR10, CXCL10, PROKR1 | ALDH1A1 3364/4885MEN1 2559/4885CYP1A2 4581/4885 |
| US-20210353765-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MAVS, NFATC1, MYD88 | ALDH1A1 2932/4885MEN1 1805/4885CYP1A2 3964/4885 |
| US-20080253961-A1 | Drug delivery; biocompatable polyesters; biodegradable glycolic acid-lactic acid nanoshell (PLGA); controlled release | LDHA, LDHB, ADSL | ALDH1A1 80/4885MEN1 4146/4885CYP1A2 2387/4885 |
| US-20220202944-A1 | OPTIMIZED PROCESS FOR DIMERIC PEPTIDE-PHOSPHOLIPID CONJUGATE | KDR, TIE1, FLT1 | ALDH1A1 3983/4885MEN1 596/4885CYP1A2 3201/4885 |
| US-20230374076-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | SGMS1, SGMS2, CERT1 | ALDH1A1 3130/4885MEN1 449/4885CYP1A2 4408/4885 |
| US-20220054476-A1 | SUSTAINED LOCAL DRUG LEVELS FOR INNATE IMMUNE AGONISTS | TLR3, TLR1, TLR9 | ALDH1A1 4083/4885MEN1 3626/4885CYP1A2 4707/4885 |
| US-11484596-B2 | Optimized process for dimeric peptide-phospholipid conjugate | KDR, TIE1, FLT1 | ALDH1A1 3983/4885MEN1 596/4885CYP1A2 3201/4885 |
| US-11760779-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | ALDH1A1 3005/4885MEN1 479/4885CYP1A2 4370/4885 |
| US-20200147236-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, CD47, STING1 | ALDH1A1 3017/4885MEN1 2130/4885CYP1A2 4332/4885 |
| US-20210214396-A1 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | SGMS1, SGMS2, CERT1 | ALDH1A1 3144/4885MEN1 445/4885CYP1A2 4425/4885 |
| US-20210346514-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MAVS, NFATC1, MYD88 | ALDH1A1 2932/4885MEN1 1805/4885CYP1A2 3964/4885 |
| US-20110286937-A1 | SYNTHETIC GLYCOLIPID-CONTAINING LIPOSOME | UGCG, SGMS2, CERT1 | ALDH1A1 4476/4885MEN1 1404/4885CYP1A2 4349/4885 |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | ALDH1A1 3962/4885MEN1 4395/4885CYP1A2 4304/4885 |
| US-12187817-B2 | Preparation of ceramide conjugates and derivatives of sphingolipid analogues | SGMS1, SGMS2, CERT1 | ALDH1A1 3055/4885MEN1 493/4885CYP1A2 4357/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | ALDH1A1 1600/4885MEN1 3457/4885CYP1A2 3948/4885 |
| US-11766483-B2 | Compounds and therapeutics uses thereof | MAVS, MYD88, CD47 | ALDH1A1 2838/4885MEN1 1387/4885CYP1A2 4141/4885 |
| US-20170157212-A1 | CDK MODULATORS AND METHODS FOR THE TREATMENT OF CANCER | CDK12, CDK1, CDKL2 | ALDH1A1 4707/4885MEN1 2698/4885CYP1A2 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.